Advanced Oncotherapy plc (AVO), the developer of next-generation proton therapy systems for cancer treatment, will hold its Annual General Meeting at 12.00 noon at the Royal Institute of British Architects, 66 Portland Place, London W1B 1AD on Thursday, 30 June 2016.
The Company will provide shareholders with a short presentation on its development so far and its future plans.
A copy of the presentation, which does not contain any previously unpublished information that could be considered price sensitive, will be available from Thursday, 30 June 2016 on the Company’s website: www.avoplc.com
|
Advanced Oncotherapy Plc |
|||
|
Michael Sinclair, Chief Executive Office |
Tel: +44 20 3617 8728 |
||
|
Nicolas Serandour, Chief Operating and Financial Officer |
|
||
|
|
|
||
|
Stockdale Securities (Nomad & Joint Broker) |
|
||
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
||
|
|
|
||
|
Beaufort Securities (Joint Broker) |
|
||
|
Jon Belliss / Elliot Hance |
Tel: +44 20 7382 8300 |
||
|
|
|
||
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
||
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
||